Ironwood Pharmaceuticals Shares Up 2.78% For The Session; NOTE: Co. Previously Entered Gastrointestinal Disease Education And Promotional Agreement With Alnylam Pharmaceuticals For Givlaari, Which Today Received FDA Approval